As of May 2026, the most current estimate of Mark Armenante's net worth comes from CoreStreet, which puts the figure at at least $113,327,531.72 (based on data through May 15, 2026). That number is tied specifically to his insider stock activity and reported holdings in Veeva Systems. A second source, GuruFocus, gives a much lower floor of at least $4 million, but that estimate is frozen at a 2016 snapshot and hasn't been updated to reflect current share prices. The honest answer is that the true figure almost certainly exceeds $113 million when you account for Armenante's broader portfolio, but no source has full visibility into his private holdings.
Mark Armenante Net Worth: How Much It Is and How It’s Estimated
Russell Cho
29 May 2026
Who is Mark Armenante?
Mark Armenante is a life-sciences technology executive and investor best known for his early involvement with Veeva Systems, the cloud software company that serves pharmaceutical and biotech clients. He joined Veeva's board of directors in January 2007, years before the company went public, which is the key financial fact that defines most of his estimated wealth. He stepped down from Veeva's board in September 2015, when industry veteran Tim Barabe took his seat.
Before Veeva, Armenante spent significant time at Siebel Systems, where he held senior sales and VP-level roles including work on the OnDemand division and managing alliances and operations. He also served as President of PharmaSystems, giving him deep pharma-software credentials before co-directing Veeva's early growth. His background explains how he landed the Veeva board seat in the first place: he brought exactly the industry relationships and product knowledge a pre-IPO life-sciences SaaS company needed.
Beyond Veeva, Armenante has maintained a wide range of board and governance roles. As of a February 2021 announcement, he was listed as a trustee of the Horological Society of New York (HSNY) and as a board member at A Collected Man, Oryn Therapeutics, Global Medical Aid, and Case Western Reserve University. The Org also lists him as a director at Oryn Therapeutics, and other sources mention an affiliation with One White Street as a founding partner. In March 2026, he appeared in a U.S. District Court (Southern District of New York) judgment as plaintiff in a case against Flying Colours Corp and Flexjet, LLC.
Mark Armenante's net worth: the latest estimate and where it comes from
The $113.3 million figure from CoreStreet is the most relevant starting point. For more background on the latest figure, see the full discussion of Mark Macon net worth and how the estimate is derived from public filings. CoreStreet explicitly describes Armenante as a major shareholder of Veeva Systems Inc. Class A shares and builds its model from SEC Form 4 insider trading records, looking at the history of stock sales combined with shares still held. This is a real methodology grounded in public filings, not guesswork. Because Veeva's share price has grown substantially since its 2013 IPO, even a relatively modest remaining position can represent tens of millions of dollars in current market value.
GuruFocus reaches a very different number, at least $4 million, because it stops its calculation at April 19, 2016 and assumes no transactions after that date. That assumption is explicitly acknowledged in the GuruFocus methodology, which also cautions that the figure may not reflect actual net worth. If you're using GuruFocus as a reference today, treat the $4 million as an outdated lower bound, not a current estimate. If you're looking for a quick comparison to other net worth estimate sources and how they arrive at different figures, see mark mastrandrea net worth.
| Source | Estimate | Data Basis | Last Updated | Key Limitation |
|---|---|---|---|---|
| CoreStreet | At least $113,327,531.72 | SEC Form 4 insider trades + current holdings in Veeva | May 15, 2026 | Excludes private holdings, non-Veeva assets |
| GuruFocus | At least $4 million | SEC Form 4 final share position | Feb 6, 2026 (data frozen at Apr 2016) | Assumes no transactions after April 19, 2016; severely outdated |
What's actually verifiable and what isn't
The most reliable piece of evidence is Veeva's 2014 annual report and proxy filings, which disclose Armenante's Class B share holdings directly and through named trust structures (including GRAT and revocable trust arrangements). That's primary-source documentation from the SEC and issuer filings. You can verify that these holdings existed and roughly how large they were during his time on the board.
What you cannot verify from public records: how many shares he retained after his April 2016 insider transaction, whether he sold additional stock through non-reportable means after the Form 4 window, what his stake in private companies like Oryn Therapeutics or One White Street is worth, or any real estate and personal asset holdings. No third-party net-worth aggregator has that data. The CoreStreet figure is best read as a floor tied to his Veeva equity story, not a ceiling.
The March 2026 court judgment involving Flying Colours Corp (a private aviation operator) and Flexjet, LLC is an interesting data point. Armenante appeared as the plaintiff, which could imply a financial dispute with a private aviation company he may have used or contracted with. The judgment document confirms the case outcome but not the financial terms, so it's impossible to draw conclusions about wealth impact from that filing alone.
The wealth drivers: how Armenante built his financial position
Veeva Systems equity
This is overwhelmingly the biggest driver. Armenante joined Veeva's board in January 2007, six years before the company's October 2013 NYSE IPO. Early board members of a successful SaaS company typically receive equity compensation in the form of stock options or restricted shares, and Veeva has been one of the stronger-performing enterprise software stocks of the past decade. The 2014 proxy shows him holding Class B shares both directly and through trust structures, which is the kind of diversified ownership setup you use when you're managing a large equity position and estate planning simultaneously.
Executive career compensation
Before and alongside the Veeva board role, Armenante accumulated salary and potentially equity compensation through his work at Siebel Systems and his presidency of PharmaSystems. Siebel was one of the dominant enterprise software companies of the late 1990s and early 2000s, so senior roles there would have come with meaningful cash and stock packages. These earlier earnings likely provided capital that contributed to his ability to take advisory and board positions rather than purely executive ones.
Board roles and private investments
His current involvement with Oryn Therapeutics, A Collected Man (a curated pre-owned watch platform), Global Medical Aid, and his affiliation with One White Street suggests an active portfolio of private investments and advisory positions. Board roles at private companies sometimes come with equity stakes rather than just cash fees, meaning Armenante may have financial exposure to a range of life-sciences and commercial ventures whose value is entirely invisible to public aggregators.
A rough financial timeline
- Pre-2007: Career income and equity from Siebel Systems and PharmaSystems provide capital base and industry credibility.
- January 2007: Joins Veeva Systems board as a founding director, likely receiving equity as part of the board package.
- October 2013: Veeva IPOs on the NYSE, converting board equity into publicly tradeable stock and creating the foundation of his current estimated wealth.
- 2014: Proxy filings confirm direct and trust-held Class B share ownership, giving the public its clearest picture of his Veeva equity position.
- September 2015: Steps down from Veeva's board; any remaining equity grants would likely have continued vesting or been already vested.
- April 19, 2016: Last recorded insider transaction on Veeva Form 4 filings. GuruFocus freezes its estimate here; CoreStreet extrapolates share value forward using current prices.
- 2021 onward: Active in multiple board and trustee roles (HSNY, Oryn Therapeutics, A Collected Man, Global Medical Aid, CWRU), suggesting continued investment activity.
- March 2026: Appears as plaintiff in Southern District of New York litigation against Flying Colours Corp and Flexjet, LLC.
- May 2026: CoreStreet's most recent estimate places net worth at at least $113.3 million.
What 'net worth' actually means here (and why the numbers vary)
Net worth is assets minus liabilities, full stop. It's not salary, it's not cash flow, and it's not what someone earns in a year. When CoreStreet says Armenante's net worth is at least $113 million, they're estimating the current market value of a stock position minus any debt secured against it (which they don't know), and they're not touching private investments, real estate, vehicles, art, watches, or any other assets. So the number is more of a partial snapshot than a complete financial picture.
The wide gap between $4 million (GuruFocus) and $113 million (CoreStreet) isn't a disagreement about facts. It's a disagreement in methodology. GuruFocus is essentially saying: here's what we can confirm he held in 2016 based on his last reported transaction. CoreStreet is saying: here's what those shares would be worth today at current market prices, based on all the transactions we've tracked. Neither figure captures everything, but CoreStreet's is far more current and reflects Veeva's real share price appreciation since 2016. If you want an at-a-glance comparison to a different estimate, see more on Mark Aramli net worth and how other insiders are valued.
One more thing worth understanding: the word 'at least' in both estimates is doing real work. It's an honest admission that public filings only capture part of someone's financial life. The more complex a person's portfolio (trusts, private companies, real estate), the bigger the gap between 'at least' and reality. For someone like Armenante, who demonstrably uses trust structures for equity and sits on multiple private company boards, the real number is almost certainly higher than any public estimate.
How to check for updates and find reliable figures
- Search the SEC's EDGAR database (sec.gov/cgi-bin/browse-edgar) for Mark A. Armenante's Form 4 filings under Veeva Systems to see any insider transactions more recent than April 2016.
- Check CoreStreet's profile page for Armenante directly, as they update their model using live stock prices applied to disclosed holdings, making their figure the most dynamically current.
- Cross-reference GuruFocus only as a historical baseline. Their 2016-frozen estimate is not useful as a current figure, but the underlying transaction history is valuable for understanding how shares were accumulated.
- Look at Veeva's most recent proxy statement on SEC EDGAR to see if Armenante still appears in any beneficial ownership tables as a major shareholder.
- Search OpenCorporates or state business registries for any new venture activity connected to his name, which could indicate private equity positions not captured in public filings.
- For litigation-linked wealth events, check PACER (Public Access to Court Electronic Records) for the Southern District of New York case involving Flying Colours Corp and Flexjet to see if financial terms have been made public.
- Set a Google Alert for 'Mark Armenante' filtered to news and public filings to catch any new disclosures, board appointments, or regulatory filings as they happen.
Putting the number in context
A $113 million-plus net worth puts Armenante firmly in the category of wealth that's built on equity in a high-growth SaaS company, not on salary or traditional executive compensation. It's a pattern you see repeatedly with early board members and investors of companies like Veeva: modest-looking roles on paper that created life-changing wealth because the equity was tied to a company that became a multi-billion-dollar enterprise. Veeva's market cap exceeded $30 billion at its peak, so even a small percentage stake held since 2007 translates to significant wealth. Other public figures in the 'Mark' space have interesting financial stories of their own, but Armenante's story is particularly clean as an example of how board-level equity at a pre-IPO SaaS company compounds over time.
If you're researching this figure for investment context, the takeaway is straightforward: Armenante's disclosed public wealth is almost entirely a function of early Veeva equity. If you're just curious about the number, $113 million is the most defensible current estimate, with the caveat that it's a floor derived from public filings and the real figure is likely higher once private holdings are factored in.
FAQ
Why do net-worth estimates for Mark Armenante differ so much (for example, $4 million vs $113 million)?
They use different cutoffs and coverage. One approach stops at an older filing date and assumes no later transactions, while the other re-values confirmed remaining shares at today’s market price. Since neither method can see private holdings, the higher figure is usually a more up-to-date valuation of the public equity component, not proof of a complete net worth.
Is the “at least” wording for Armenante’s net worth basically the true number?
No. “At least” means a confirmed floor from public disclosures, after accounting for known share sales and publicly visible holdings. It does not include private-company equity, real estate, personal trusts without disclosed values, or debt levels that could reduce net worth.
How can I estimate Armenante’s Veeva stake more precisely using public filings?
Focus on the most recent Form 4 filings and annual proxy disclosures that list Class B holdings and any trust structures (for example, GRAT or revocable trusts). Then apply the current Veeva share price to the confirmed share count, but also watch for conversion terms or class differences that can affect how market value is modeled.
Does Armenante’s board membership on Veeva guarantee he had equity that drove the wealth figure?
Not guaranteed in a direct one-to-one way. Board roles can come with different equity grants depending on the year and compensation plan. However, the article’s methodology treats disclosed insider activity and remaining holdings as the key evidence, so the wealth estimate is anchored to what filings show, not only to the fact of being on the board.
Could Armenante’s private-investment stakes (such as Oryn Therapeutics or One White Street) be worth more than the public Veeva-based estimate?
Yes, potentially. Private equity and startup stakes can be worth far more (or far less) than implied at the time of investment, and public aggregators typically cannot observe fair value. Unless a private company reports valuations through credible transactions or filings, those values are usually not incorporated into net-worth estimates.
What does “insider stock activity” tell you, and what does it not tell you?
It tells you when he bought or sold shares that triggered disclosure requirements, and it can show what he still held afterward. It does not reliably capture sales outside reporting windows, transactions that were not reportable under the SEC rules, or any debt, taxes, and hedging that change the final net-worth impact.
Could trust structures make Armenante’s actual ownership hard to interpret from net-worth articles?
Yes. Shares held through trusts can be reflected in filings without being straightforward to map to direct ownership and current access to liquidation proceeds. If you are modeling value, read the specific trust and share class language in issuer documents, not just the headline number in a summary article.
Does Veeva’s share price appreciation since the IPO automatically translate into Armenante’s net worth?
Only if his relevant shares were still held when the price moved. If he sold a substantial portion earlier, the later appreciation would not apply to the proceeds. The critical link is the remaining-share count after the last disclosed transactions, which is why different sources using different snapshots can diverge.
How do analysts typically treat debt in net worth estimates for someone like Armenante?
Most public-derived estimates for wealthy executives are effectively assets-only floors, because liabilities and margin loans secured by stock are not consistently disclosed in an easy, complete way. That means the figure could overstate net worth if significant debt exists against the equity holdings, but neither CoreStreet nor GuruFocus can confirm that debt level from public data alone.
Is the March 2026 court judgment relevant to Mark Armenante’s net worth?
Not in a measurable way from public information. Court outcomes may indicate who won a dispute, but most judgments do not disclose total damages in a form that can be reliably converted into changes in personal wealth. Treat it as context, not a quantitative adjustment to net worth.
If I want the most defensible estimate for today, which number should I treat as closer to reality?
Treat the CoreStreet-style figure as the better current proxy for the publicly observable Veeva equity component, because it is re-valued and not frozen at a 2016 snapshot. Still treat it as a floor, because the same limitations still apply to private holdings and liabilities that aggregators cannot fully observe.
Next Article
Mark Abma Net Worth: How It’s Estimated and What We Know
Find Mark Abma net worth estimate with identity check, wealth breakdown, and tips to verify sources and spot outdated cl
